Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of the American Academy of Dermatology https://doi.org/10.1016/j.jaad.2026.02.025 Dr. Frank Siebenhaar et al.
Points
- Researchers at the University of Basel used artificial intelligence to quantitatively measure the reduction of skin lesions in two hundred twelve patients suffering from the rare disease mastocytosis.
- The study found that patients treated with the drug avapritinib experienced an average thirty-six point six percent decrease in the total area covered by painful and itchy skin lesions.
- AI software analyzed standardized photographs taken under controlled conditions to provide a more accurate assessment of lesion size and color normalization than is possible with the human eye alone.
- Biopsy results confirmed that the clinical improvements seen on the skin were directly linked to a significant decrease in the number of mast cells within the affected tissue areas.
- While the AI tool proved valuable for precise quantification in clinical trials experts noted that human dermatologists remain essential for distinguishing between pathological lesions and common moles.
Summary
Evaluated the efficacy of avapritinib in treating cutaneous manifestations of mastocytosis, a rare myeloid neoplasm characterized by the uncontrolled proliferation of mast cells. Utilizing a novel artificial intelligence (AI) framework developed at the University of Basel, investigators sought to quantitatively measure changes in skin lesion area and pigmentation over a 24-week period. The study aimed to provide a more precise alternative to traditional visual assessments, which often struggle to reliably capture subtle changes in small, multifocal lesions.
The findings from 212 subjects demonstrated significant therapeutic benefit following administration of the KIT inhibitor. In a subset of 111 participants who underwent standardized longitudinal photography, AI-driven analysis revealed that the total area of skin lesions decreased by an average of 36.6%. Furthermore, histopathological evaluations via skin biopsies confirmed a concurrent reduction in the density of mast cells within the dermis. These quantitative improvements were accompanied by normalized lesion coloration and reported enhancements in patient-reported quality of life metrics, including a reduction in pruritus and hives.
The results suggest that AI-integrated dermatological assessment represents a groundbreaking advancement for clinical trial methodology. While the AI successfully automated the highlighting of mastocytosis-specific lesions, a feedback loop with experienced dermatologists was necessary to differentiate between pathological lesions and benign nevi. These findings indicate that while AI cannot currently replace tactile clinical expertise, it provides an essential tool for the precise quantification of treatment response. Avapritinib’s approval for severe mastocytosis highlights the potential for this technology to standardize the evaluation of various complex skin diseases in future research.
Link to the article: https://pubmed.ncbi.nlm.nih.gov/41690487
References
Siebenhaar, F., Broesby-Olsen, S., Castells, M., George, T. I., Livideanu, C. B., Alvarez-Twose, I., Panse, J., Barete, S., Reiter, A., Dybedal, I., Akin, C., Van Daele, P., Radia, D. H., Cerquozzi, S., Ustun, C., Sabato, V., Gotlib, J., Rafferty, M., DeAngelo, D. J., … Hartmann, K. (2026). Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study. Journal of the American Academy of Dermatology, S0190962226002215. https://doi.org/10.1016/j.jaad.2026.02.025
